Literature DB >> 115811

Nutritional concepts in the treatment of head and neck malignancies.

E M Copeland, J M Daly, S J Dudrick.   

Abstract

Cancer cachexia should no longer be a contraindication to adequate antineoplastic treatment. Current methods of nutritional assessment allow one to identify malnutrition and to follow the nutritional status of the patient throughout the cancer-management program. Enteral nutritional repletion and maintenance remain the ideal course of action, but the gastrointestinal tract is not always readily available or advisable for use; in such circumstances, intravenous hyperalimentation (IVH) may be indicated. The properly nourished patient better tolerates cancer therapy, experiences fewer complications of malnutrition (e.g., sepsis and poor wound healing), and has a better-functioning immune system than does his malnourished counterpart. This article reviews methods of nutritional assessment, delineates indications and techniques for nutritional repletion, and summarizes the results obtained.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 115811     DOI: 10.1002/hed.2890010408

Source DB:  PubMed          Journal:  Head Neck Surg        ISSN: 0148-6403


  3 in total

1.  Prevention and Treatment of Postsurgical Head and Neck Infections.

Authors:  Rebecca Fraioli; Jonas T. Johnson
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

2.  Factors Affecting Postoperative Complications After Reconstructive Surgery in Oral Carcinoma Patients: A Prospective Study of 100 Patients.

Authors:  Prateek Vijay Jain; Bhavesh Bang; Kapila Manikantan; Tiash Sinha; Gautam Biswas; Pattatheyil Arun
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-03-19

3.  Modified radiology-guided percutaneous gastrostomy (MRPG) for patients with complete obstruction of the upper digestive tract and who are without endoscopic or nasogastric access.

Authors:  Siu-Cheung Chan; Winnie Chiu-Wing Chu; Kar-Wai Liu; Chun-Ta Liao; Tsung-Shih Lee; Shu-Hang Ng
Journal:  Korean J Radiol       Date:  2011-03-03       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.